Agile Therapeutics, Inc.

AGRX

US00847L3087

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:51:40 18/07/2024 am IST			5-day change	1st Jan Change
1.44 ^USD	+0.70%		+0.70%	-26.15%

26/06	Exeltis USA, Inc. entered into a definitive merger agreement to acquire Agile Therapeutics, Inc. for $10.7 million.	CI
15/05	Agile Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

January 09, 2023 at 05:30 pm IST

Agile Therapeutics, Inc. provided revenue guidance for the full year 2023. For the period, the company expects net revenue to be in the range of $25 million - $30 million.

Latest news about Agile Therapeutics, Inc.

Exeltis USA, Inc. entered into a definitive merger agreement to acquire Agile Therapeutics, Inc. for $10.7 million.	26/06	CI
Agile Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q1 Revenue $5.7M	16/05	MT
Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024	28/03
Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M	28/03	MT
Agile Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03	CI
Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from S&P TMI Index	28/03	CI
Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from NASDAQ Composite Index	25/03	CI
North American Morning Briefing : Stocks Struggle After New Records	22/03	DJ
North American Morning Briefing : Stock Futures -2-	19/03	DJ
Maxim Downgrades Agile Therapeutics to Hold From Buy	18/03	MT
Agile Therapeutics Inc. Completes Pay-Off the Remainder of its Debt Facility	15/03	CI
Top Premarket Gainers	22/02	MT
Agile Therapeutics, Inc. Announces Senior Secured Term Loan Credit Facility of Up to $35.0 Million	16/02	CI
Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year Ended December 31, 2023	16/02	CI
Agile Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Transcript : Agile Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023	09/11
Agile Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023	09/11	CI
Earnings Flash (AGRX) AGILE THERAPEUTICS Reports Q3 Revenue $6.7M, vs. Street Est of $6.35M	09/11	MT
North American Morning Briefing : Traders Await -2-	09/11	DJ
North American Morning Briefing : Stock Futures -2-	25/23/25	DJ
Maxim Upgrades Agile Therapeutics to Buy From Hold With $5 Price Target	22/23/22	MT
Agile Therapeutics, Inc. Affirms Revenue Guidance for the Year 2023	09/23/09	CI
Transcript : Agile Therapeutics, Inc., Q2 2023 Earnings Call, Aug 09, 2023	09/23/09
Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q2 Revenue $5.5M	09/23/09	MT

Chart Agile Therapeutics, Inc.

Duration

Period

More charts

Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
AGILE THERAPEUTICS, INC.	-26.15%	9.8M
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	118B
ARGENX SE	+23.26%	27.87B
BIONTECH SE	-18.07%	20.95B
GENMAB A/S	-15.13%	16.92B
BEIGENE, LTD.	-14.81%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.84B
WUXI APPTEC CO., LTD.	-46.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+52.34%	14.08B

Bio Therapeutic Drugs